Subscribe
shutterstock_1086968018_jarretera-2
Jarretera / Shutterstock.com
13 May 2019Americas

Diabetics to benefit under latest FDA biosimilar guidance

The Food and Drug Administration (FDA) has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

article
FDA to alter biosimilar ‘suffix’ policy
8 March 2019   The US Food and Drug Administration yesterday announced draft revisions to its policy on the naming of biosimilars, in an attempt to appease critics who say that renaming previously-licensed products is too expensive.
Biotechnology
FDA releases plan to boost biosimilars development
13 December 2018   The US Food and Drug Administration has announced new measures to advance the development of biosimilar medicines.
Americas
US Congress confirms new drug patent listing law
22 December 2020   A $2.3 trillion spending bill passed by the US Congress yesterday, December 21 includes a proposed change to the laws concerning biologic drugs.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

article
FDA to alter biosimilar ‘suffix’ policy
8 March 2019   The US Food and Drug Administration yesterday announced draft revisions to its policy on the naming of biosimilars, in an attempt to appease critics who say that renaming previously-licensed products is too expensive.
Biotechnology
FDA releases plan to boost biosimilars development
13 December 2018   The US Food and Drug Administration has announced new measures to advance the development of biosimilar medicines.
Americas
US Congress confirms new drug patent listing law
22 December 2020   A $2.3 trillion spending bill passed by the US Congress yesterday, December 21 includes a proposed change to the laws concerning biologic drugs.

More on this story

article
FDA to alter biosimilar ‘suffix’ policy
8 March 2019   The US Food and Drug Administration yesterday announced draft revisions to its policy on the naming of biosimilars, in an attempt to appease critics who say that renaming previously-licensed products is too expensive.
Biotechnology
FDA releases plan to boost biosimilars development
13 December 2018   The US Food and Drug Administration has announced new measures to advance the development of biosimilar medicines.
Americas
US Congress confirms new drug patent listing law
22 December 2020   A $2.3 trillion spending bill passed by the US Congress yesterday, December 21 includes a proposed change to the laws concerning biologic drugs.

More features

President Trump 2.0: Five major areas to watch
China’s new policies on foreign investment in healthcare and biotech
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug